CA-BELKIN
25.6.2024 17:01:34 CEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced the availability of the BoostCharge Pro Magnetic Power Bank, built with Qi2 wireless charging technology. It is available to order today in 5K and 10K options, and in five fresh new colors – cyber lime, sand, pink, blue, and gold.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625730951/en/
Belkin BoostCharge Pro Magnetic Power Bank 5K in cyber lime, sand, pink, blue and gold color options. (Photo: Business Wire)
Unveiled earlier this year, Belkin’s Qi2 power bank lineup delivers up to 15W of fast charging power for iPhone 12 models and later, without the hassle of cables. They are engineered with an integrated kickstand for propping the phone up while streaming, reading or chatting, and work with magnetic and MagSafe cases up to 3mm thick. They are designed to fit perfectly on the back of iPhone without obstructing camera. “Power pass-through” allows for charging the power bank and attached devices in one simple action via USB-C port.
BoostCharge Pro Magnetic Power Bank 5K
- Fast charges iPhone 12 models and later up to 15W with Qi2 when battery pack is plugged in, and up to 7.5W when used as battery pack
- Provides up to 16 hours of additional battery life1
- Built with 1 x USB-C port to charge two devices simultaneously2
- Packaged with USB-C to USB-C cable to start charging right out of the box
- Available in black, cyber lime, sand, pink, and blue color options; gold available in European markets only
- $59.95 USD
BoostCharge Pro Magnetic Power Bank 10K
- Fast charges iPhone 12 models and later up to 15W with Qi2 (delivers 0-25% charge in 21 minutes3), or up to 20W with integrated USB-C cable
- Provides up to 35 hours of additional battery life4
- Built with 1 x USB-C port and integrated USB-C cable to charge three devices simultaneously5
- Available in black
- $99.95 USD
In line with Belkin’s commitment to build products more responsibly, the BoostCharge Pro Magnetic Power Bank offerings are made with a minimum of 72% post-consumer recycled materials (PCR) and packaged in 100% plastic-free packaging.
Media kit can be found HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
___________
1 Maximum additional video playback hours calculated by comparing the mAh capacity of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on differing factors for individual users.
2 When one device is charging: 7.5W wireless or USB-C 12W max output. When two devices are charging: 5W wireless + 5W max USB-C
3 Based on internal tests using iPhone 15; results may vary depending on various conditions.
4 Contains a 10,000 mAh internal battery. Amount of discharge to user’s device is less and may vary depending on various conditions. Maximum additional video playback hours calculated by comparing the capacity of the internal battery of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on conditions and use.
5 When one device is charging: 15W wireless, or USB-C 20W max output. When two devices charging: 7.5W wireless + 10W max USB-C. When three devices charging: 15W max shared
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625730951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
